GMP Viral Vectors BioNTech IMFS provides development and production of viral vectors, cells and IVT mRNA in state of the art GMP facilities and offers contract services for retroviral vector manufacturing for clinical supply, presenting a strong CDMO option for gene therapy and mRNA programs.

EU Based CDMO As a Germany based subsidiary of BioNTech SE with established facilities and regulatory experience, BioNTech IMFS can serve as a European CDMO partner for clinical grade manufacturing and regulatory aligned supply of viral vectors and mRNA products.

Retroviral Vector Focus The company emphasizes retroviral vector manufacturing for clinical supply, offering a niche capability to biotech and pharma sponsors developing gene therapies such as CAR T and related products, enabling scalable process development and manufacturing partnerships.

Digital and Compliance Readiness A mature IT and data ecosystem featuring SAP SuccessFactors and Oracle, plus standard web security and analytics tools, indicates a foundation for compliant scalable manufacturing operations and potential for IT integrations, MES and LIMS modernization, and data driven process optimization.

Talented Collaboration A skilled, growing workforce with ongoing hiring indicates opportunities for talent development partnerships, joint training programs, and collaboration on talent pipelines to support scale up of manufacturing for complex biologics.